2013-2014 Updates in Peyronie's disease management - Abstract

The number of patients presenting with Peyronie's disease (PD) appears to be on the rise.

This review provides an analysis of pertinent recent updates in the management of PD, focusing on data published within the past year. Objective benefit from injectable agents has been reported for years in mostly noncontrolled trials. The safety and efficacy of injectable collagenase clostridium histolyticum is now supported by data from a large-scale phase III randomized controlled trial. Other important advances have also been made in the surgical management of Peyronie's disease, including new modifications to proven surgical techniques and a variety of approaches that can help enhance and restore penile length.

Written by:
Sherer BA, Warrior K, Levine LA.   Are you the author?
Rush University Medical Center, Suite 348, 1725 Harrison St, Chicago, IL, 60612, USA.  

Reference: Curr Urol Rep. 2014 Dec;15(12):459.
doi: 10.1007/s11934-014-0459-5

PubMed Abstract
PMID: 25287257

UroToday.com Peyronie's Section


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.